Want to see RBOT full AI Analyst Report?
Top Page
Vicarious Surgical
(OTC:RBOT)
Select Model
Select Model
Rating:39Underperform
Price Target:
$0.03
▼(-15.00% Downside)
Action:Reiterated
Date:08/18/26
The score is driven primarily by weak financial performance (pre-revenue, heavy cash burn, and a sharply eroded equity base versus debt) and a materially negative corporate event (approved liquidation/dissolution with creditors prioritized). Technicals further reflect severe downside pressure (price far below key moving averages with negative MACD), while valuation metrics are not supportive given ongoing losses and no dividend yield data.
Positive Factors
Narrowing losses
Losses had been narrowing, indicating some progress in reducing operating expenses and development spending. However, this improvement had not produced revenue or profitability and is unlikely to matter after the approved liquidation.
Negative Factors
Approved liquidation and dissolution
The approved wind-down is a fundamental impairment of the business rather than a temporary setback. Assets are being transferred for creditors, public reporting is ending, and board and executive departures substantially reduce the prospect of continuing operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing losses
Losses had been narrowing, indicating some progress in reducing operating expenses and development spending. However, this improvement had not produced revenue or profitability and is unlikely to matter after the approved liquidation.
Read all positive factors
Vicarious Surgical (RBOT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$274.20K
Dividend YieldN/A
Average Volume (3M)90.39K
Price to Earnings (P/E)―
Beta (1Y)2.19
Revenue GrowthN/A
EPS Growth36.00%
CountryUS
Employees48
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-6.75
Shares Outstanding6,477,365
10 Day Avg. Volume138,739
30 Day Avg. Volume90,387
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.07
Revenue Forecast (FY)N/A
Vicarious Surgical Business Overview & Revenue Model
Company Description
Vicarious Surgical Inc. is dedicated to the development and commercialization of advanced single-incision surgical robotics. Their innovative technology is designed to give surgeons a virtual, immersive presence within the patient's body, facilita...
How the Company Makes Money
As of publicly available information through 2025, Vicarious Surgical has been primarily a development-stage company and, to the extent it has had revenue, it has not been driven by broad commercial sales of its surgical robot. The company’s inten...
Vicarious Surgical Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Neutral
The earnings call reflects a company focused on reducing costs and improving operational efficiency, evident from significant reductions in operating expenses and successful fundraising efforts. However, challenges remain with high cash burn and potential disruptions due to outsourcing efforts. Additionally, the company has had to reduce its workforce to control costs.Positive Updates
Significant Reduction in Operating Expenses
Total operating expenses for Q3 2025 were $11.5 million, a 35% decrease compared to $17.8 million in Q3 2024.
Negative Updates
Continued High Cash Burn
The company continues to expect full year 2025 cash burn to be approximately $50 million, with a Q3 cash burn rate of approximately $10.5 million.
Read all updates
Q3-2025 Updates
Positive
Negative
Significant Reduction in Operating Expenses
Total operating expenses for Q3 2025 were $11.5 million, a 35% decrease compared to $17.8 million in Q3 2024.
Read all positive updates
Company Guidance
In the Vicarious Surgical's 2025 Third Quarter Earnings Call, the company outlined its guidance and strategic focus areas. The primary objectives include achieving a design freeze for their production-equivalent system by the end of 2026 and reducing cash burn. Operating expenses for the quarter decreased by 35% to $11.5 million compared to the same period in 2024, with specific reductions in R&D, general and administrative, and sales and marketing expenses. The company reported a GAAP net loss of $11.1 million or $1.86 per share for the quarter. Vicarious Surgical ended the quarter with $13.4 million in cash and investments, and a cash burn rate of approximately $10.5 million. They aim to keep the full-year 2025 cash burn around $50 million, with plans to reduce it further in 2026 through outsourcing and restructuring. Additionally, a registered direct offering post-Q3 added $5.2 million in net proceeds. The company intends to improve communication with stakeholders via updates on LinkedIn and their Investor Relations website.Vicarious Surgical Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
28
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -826.00K | -1.43M | -2.11M | -1.85M | 0.00 | 0.00 |
| EBITDA | -40.88M | -48.76M | -61.12M | -69.19M | 6.47M | -34.80M |
| Net Income | -42.12M | -50.18M | -63.22M | -71.07M | 5.16M | -35.21M |
Balance Sheet | ||||||
| Total Assets | 12.59M | 19.58M | 67.72M | 119.86M | 140.29M | 181.68M |
| Cash, Cash Equivalents and Short-Term Investments | 3.68M | 9.79M | 49.10M | 98.18M | 116.21M | 173.51M |
| Total Debt | 7.20M | 7.79M | 13.79M | 14.83M | 15.69M | 1.34M |
| Total Liabilities | 9.02M | 9.74M | 21.02M | 21.89M | 29.25M | 98.59M |
| Stockholders Equity | 3.57M | 9.84M | 46.70M | 97.97M | 111.05M | 83.09M |
Cash Flow | ||||||
| Free Cash Flow | -39.68M | -45.21M | -50.14M | -63.98M | -66.56M | -34.59M |
| Operating Cash Flow | -39.55M | -45.08M | -49.96M | -62.30M | -61.21M | -33.30M |
| Investing Cash Flow | 32.53M | 32.15M | 6.86M | -45.78M | -5.35M | -1.29M |
| Financing Cash Flow | 5.59M | 5.76M | 8.00K | 44.70M | 9.14M | 192.16M |
Vicarious Surgical Technical Analysis
Negative
0.04
Price Trends
0.12
Negative
0.39
Negative
1.23
Negative
Market Momentum
-0.03
Negative
20.71
Positive
31.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBOT, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.12, and below the 200-day MA of 1.23, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 20.71 is Positive, neither overbought nor oversold. The STOCH value of 31.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RBOT.
Vicarious Surgical Risk Analysis
Vicarious Surgical disclosed 77 risk factors in its most recent earnings report. Vicarious Surgical reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vicarious Surgical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.79B | 13.05 | 17.62% | ― | 4.35% | 161.83% | |
69 Neutral | $4.41B | 23.20 | 15.41% | ― | 12.39% | ― | |
55 Neutral | $79.80M | -1.00 | -62.25% | ― | -1.26% | 79.82% | |
54 Neutral | $1.21B | -10.62 | -30.62% | ― | 22.69% | -25.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $45.03M | -4.01 | -23.45% | ― | -14.27% | -132.84% | |
39 Underperform | $274.20K | >-0.01 | -333.19% | ― | ― | 36.00% |
* Healthcare Sector Average
RBOT
Vicarious Surgical
0.04
-6.30
-99.40%
LIVN
LivaNova
80.03
24.58
44.33%
XTNT
Xtant Medical Holdings
0.33
-0.30
-47.62%
INSP
Inspire Medical Systems
60.82
-30.64
-33.50%
OM
Outset Medical
4.09
-9.83
-70.62%
PRCT
PROCEPT BioRobotics
20.60
-19.74
-48.93%
Vicarious Surgical Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesRegulatory Filings and ComplianceShareholder Meetings
Vicarious Surgical Approves Liquidation and Dissolution Plan
Negative
Jul 21, 2026
On July 21, 2026, Vicarious Surgical’s stockholders and board approved the transfer of all or substantially all company assets to Vicarious Liquidation, LLC via a general assignment for the benefit of creditors, and simultaneously endorsed a...
Business Operations and StrategyExecutive/Board Changes
Vicarious Surgical Announces Upcoming Chief Financial Officer Resignation
Neutral
Jun 24, 2026
On June 24, 2026, Vicarious Surgical disclosed that Chief Financial Officer Sarah Romano has submitted her resignation, with her departure slated to take effect on July 22, 2026, or a later mutually agreed date. The company emphasized that Romano&...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.